Cancer incidence and mortality patterns in Europe: Estimates for 40 countries in 2012, European Journal of Cancer, vol.49, issue.6, pp.1374-403, 2013. ,
DOI : 10.1016/j.ejca.2012.12.027
The pattern of recurrent colorectal cancer in a prospective randomised study and the characteristics of diagnostic tests, International Journal of Colorectal Disease, vol.12, issue.6, pp.329-363, 1997. ,
DOI : 10.1007/s003840050118
Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study, Annals of Oncology, vol.69, issue.7, pp.1535-1581, 2011. ,
DOI : 10.1158/0008-5472.CAN-08-2466
Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer, New England Journal of Medicine, vol.360, issue.14, pp.1408-1425, 2009. ,
DOI : 10.1056/NEJMoa0805019
Mutations in Colorectal Cancer, New England Journal of Medicine, vol.369, issue.11, pp.1023-1057, 2013. ,
DOI : 10.1056/NEJMoa1305275
URL : https://hal.archives-ouvertes.fr/hal-02109307
The KRAS mutation detection within the initial management of patients with metastatic colorectal cancer: A status report in France in 2011, European Journal of Cancer, vol.49, issue.9, pp.2126-2159, 2013. ,
DOI : 10.1016/j.ejca.2013.02.016
URL : https://hal.archives-ouvertes.fr/hal-00974915
, Summary of Product Characteristics. Erbitux® (cetuximab), last updated 27, 2014.
, Summary of Product Characteristics Vectibix® (panitumumab), last updated 26, 2015.
, Observational study on conditions for access to the